Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Docetaxel and prostate cancer].

Jean-Marc Ferrero1

  • 1Service d'oncologie médicale, Centre Antoine-Lacassagne, Nice. jean-marc.ferrero@cal.nice.fnclcc.fr

Bulletin Du Cancer
|March 30, 2004
PubMed
Summary

Hormone-refractory prostate cancer (HRPC) treatment options are limited. Combining docetaxel and estramustine shows promise for HRPC patients, improving response rates and clinical benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small Is Beautiful: Is ctDNA Ready for Routine Implementation in Cancer Management?

Cancers·2026
Same author

Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

Breast (Edinburgh, Scotland)·2026
Same author

Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Rethinking EPO: A Paradigm Shift in Oncology?

Cancers·2025
Same author

PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

De-Escalating Anticancer Treatment: Watch Your Step.

Cancers·2025

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer is a leading cause of cancer death in men, with limited options once metastasized and refractory to hormone therapy.
  • Current palliative treatments for advanced prostate cancer, such as castration and anti-androgens, are effective initially but often fail within 12-18 months.
  • Few effective alternatives exist for patients with hormone-refractory prostate cancer (HRPC).

Purpose of the Study:

  • To evaluate the efficacy of combining docetaxel and estramustine in treating advanced prostate cancer.
  • To assess the impact of this combination therapy on prostate-specific antigen (PSA) response rates and objective tumor response.
  • To compare the combination therapy's effectiveness against existing treatments like mitoxantrone.

Main Methods:

  • Review of Phase II trials investigating docetaxel monotherapy and its combination with estramustine.
  • Analysis of a randomized Phase II trial comparing docetaxel-estramustine combination with mitoxantrone.
  • Evaluation of biochemical response rates (PSA) and objective response rates.

Main Results:

  • Docetaxel monotherapy demonstrated PSA response rates of 45-58% and objective response rates of 33-40%.
  • Combination therapy with docetaxel and estramustine increased biochemical response rates to 74%.
  • A randomized Phase II trial showed superiority of the docetaxel-estramustine combination over mitoxantrone regarding response rate and clinical benefit.

Conclusions:

  • The combination of docetaxel and estramustine is a promising therapeutic strategy for hormone-refractory prostate cancer.
  • This combination therapy appears to improve response rates and clinical benefits compared to mitoxantrone.
  • Further Phase III trials are needed to confirm survival benefits and establish optimal treatment protocols.

Related Experiment Videos